Study suggests improved efficiency of cancer drug development process
According to a recent analysis by Tufts Center for the Study of Drug Development (CSDD) researchers, clinical success rates for new cancer drugs increased from 9.9% in the mid-1990s to 19.8% in the early 2000s. The investigation also showed that the number of new cancer drugs beginning clinical testing during this period increased by 50%.
Study leader Joseph A. DiMasi, Tufts CSDD director of economic analysis, said, “That success rates increased during the 12 years we examined suggests, while drug development remains highly complex, drug companies are making headway in improving the development process.”
Source: Tufts Center for the Study of Drug Development Press Release.